Cartesian Therapeutics Engages Investors at Conferences
PremiumCompany AnnouncementsCartesian Therapeutics Engages Investors at Conferences
29d ago
Cartesian Therapeutics reports Q2 EPS 54c, consensus ($1.07)
Premium
The Fly
Cartesian Therapeutics reports Q2 EPS 54c, consensus ($1.07)
29d ago
Cartesian Therapeutics Announces New Employment Inducement Grants
Premium
Press Releases
Cartesian Therapeutics Announces New Employment Inducement Grants
30d ago
Cartesian Therapeutics price target raised to $43 from $38 at Canaccord
PremiumThe FlyCartesian Therapeutics price target raised to $43 from $38 at Canaccord
2M ago
Cartesian Therapeutics price target lowered to $49 from $54 at H.C. Wainwright
Premium
The Fly
Cartesian Therapeutics price target lowered to $49 from $54 at H.C. Wainwright
2M ago
Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik
Premium
Press Releases
Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik
2M ago
Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis
PremiumPress ReleasesCartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis
2M ago
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
Premium
Press Releases
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
2M ago
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
Premium
Press Releases
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100